Bottom line
NMAVX vs IWP: the short answer
NMAVX (Nuance Mid Cap Value Fund) and IWP (iShares Russell Mid-Cap Growth ETF) are both mutual funds.
But IWP is far broader, holding 285 positions to 62 for NMAVX, so beyond the top names it adds exposure NMAVX doesn't have.
IWP is cheaper at 0.23% vs 1.21% — a difference of $98 a year per $10,000 invested.
Over five years, IWP returned +6.4% a year vs +3.1% for NMAVX.
NMAVX has a front-end sales load of up to 5%; the other does not.
Updated Nov 19, 2026
NMAVX vs IWP side by side
| NMAVX | IWP | |
|---|---|---|
| Type | Mutual fund | ETF |
| Fund family | Tortoise | iShares |
| Category | Mid-Cap | Mid-Cap |
| Expense ratio | 1.21% | 0.23% |
| Annual cost per $10k | $121 | $23 |
| 10-yr cost on $10k (prospectus) | $2,002 | $293 |
| Max front load | 5% | None |
| 12b-1 fee | 0.25% | 0% |
| 1-yr return | −1.4% | +8.5% |
| 5-yr return (annualized) | +3.1% | +6.4% |
| 10-yr return (annualized) | +7.6% | +12.3% |
| Best quarter | +15.3% | +30.2% |
| Worst quarter | −19.3% | −21.1% |
| Net assets (fund) | $294.8M | $20.7B |
| Number of holdings | 62 | 285 |
| Portfolio turnover | 11% | 26% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Holdings overlap
NMAVX and IWP share none of their top holdings.
NMAVX top 10
- Qiagen Nv — 7.19%
- First American Government Obli — 6.60%
- California Water Service Group — 5.82%
- Beiersdorf AG — 5.70%
- Clorox Co/The — 5.27%
- Kenvue Inc — 3.48%
- Charles Schwab Corp — 3.37%
- Solventum Corp — 3.01%
- Bio-Techne Corp — 2.98%
- Henkel AG & Co KGaA — 2.78%
IWP top 10
- BlackRock Funds III — 5.56%
- ROBLOX Corp. — 2.74%
- Royal Caribbean Cruises Ltd. — 2.65%
- Howmet Aerospace, Inc. — 2.55%
- Vistra Corp. — 2.15%
- Cloudflare, Inc. — 2.14%
- Hilton Worldwide Holdings, Inc. — 1.94%
- Vertiv Holdings Co. — 1.86%
- Cencora, Inc. — 1.85%
- Alnylam Pharmaceuticals, Inc. — 1.84%
FAQ
What is the difference between NMAVX and IWP?
Which is cheaper, NMAVX or IWP?
Should I own both NMAVX and IWP?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.